Fig. 7: CONSORT flow diagram.

Of the 53 patients recruited, 16 violated the inclusion/exclusion criteria, and 6 withdrew their informed consent, resulting in the final enrolment of 31 patients. The dose of eliglustat used in the early part of the trial was 84 mg, and after no dose-related toxicity was observed clinically, the remaining 13 patients were given a dose of 168 mg. Eliglustat was administered once daily for the first 14 days and then every other week until the 24th week. For participants who continued to benefit from the trial, eliglustat was administered daily every other week up to 96 weeks. Immune checkpoint inhibitors were administered intravenously on Day 5 or Day 15 every 3 weeks. For subjects whose greatest lesion diameter was ≥3 cm, immune checkpoint inhibitors were administered on Day 5. For subjects whose greatest lesion diameter was <3 cm, immune checkpoint inhibitors were administered on Day 15. ELI eliglustat.